Legend Biotech's CAR-T Therapy Generates $343M in H1 Sales; Philips Recalls Multiple Ventilators in U.S., Two Models Available in China
Legend Biotech
Tumor Cell Immunotherapy Developer
Johnson & Johnson
Medical Device R&D and Manufacturer
SK Biopharmaceuticals
A biopharmaceutical company
Philips ventilators encounter issues.
Recently, the U.S. Food and Drug Administration (FDA) issued an announcement recalling several models of ventilators produced by Philips with the highest level recall order. These products are mainly used to treat obstructive sleep apnea syndrome. However, due to the failure of the ventilator's malfunction alarm, it may cause treatment interruption or failure, and could even lead to serious consequences such as hypoventilation, hypoxemia, hypercapnia, respiratory failure, or death in critically ill patients.
According to media reports, two of the currently recalled products have already entered the Chinese market.
Johnson & Johnson Releases Financial Report.
On July 17, Johnson & Johnson released its second-quarter financial report, showing sales of $22.447 billion, a year-on-year increase of 4.3%; the adjusted net profit was $6.840 billion, a year-on-year increase of 1.6%. In Johnson & Johnson's revenue, the CAR-T therapy Carvykti, developed in collaboration with Legend Biotech, achieved sales of $186 million in Q2, with a total sales amount of $343 million in the first half of the year, representing a year-on-year increase of 81.5%.
Johnson & Johnson expects that the companySales in 2024The amount will reach 88 billion to 88.4 billion US dollars. What do you think of this forecast?
Chinese-produced radiopharmaceuticals go international.
On July 17, Fluoropharm announced that it had granted SK Biopharmaceuticals the global exclusive rights to FL-091, a radiopharmaceutical targeting cancers positive for Neurotensin Receptor 1 (NTSR1). The total value of the deal is $571.5 million, including upfront payments, R&D and commercial milestone payments, as well as royalties not included in the calculation.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Fluence Nuclear Medicine Out-License
On July 17, Fluorine Link Technology announced that it has granted SK Biopharmaceuticals the exclusive global rights for clinical research, development, manufacturing, and commercialization of the radiopharmaceutical FL-091, targeting cancers positive for Neurotensin Receptor 1 (NTSR1). The total value of the deal is $571.5 million, including upfront payments, R&D and commercial milestone payments, with royalties not included in this amount.
2) Someone is selling "oral semaglutide"? Novo Nordisk responds
Recently, many products have been advertised with claims such as "oral semaglutide" and "oral GLP-1," and some even assert that they "have a technical collaboration with Novo Nordisk." In response to the situation, Novo Nordisk stated that it has never engaged in such collaborations with any third parties in China.
3) Eisai grants Sato Pharmaceutical exclusive development and commercialization rights for Fluconazole in Asia and Oceania
On July 17, Eisai China announced that Eisai and Sato Pharmaceutical had reached a licensing agreement regarding the development and commercialization rights of the antifungal drug Fosravuconazole in the Asia/Oceania region. According to the agreement, Eisai exclusively licensed the intellectual property rights of Fosravuconazole in the aforementioned countries/regions to Sato Pharmaceutical.
4) Boya Biologics Plans to Acquire 100% Equity of Green Cross Hong Kong
On July 17, Boya Bio-pharmaceutical announced that the company plans to use its own funds of 1.82 billion yuan to acquire 100% equity of Green Cross Hong Kong Holdings Limited by agreement, thereby indirectly acquiring Green Cross (China) Biological Products Co., Ltd., a domestic blood products entity.
5) A controlling subsidiary of Luoxin Pharmaceutical passes the FDA inspection in the United States
On July 17, Luoxin Pharmaceutical announced that its subsidiary, Luoxin Anruowei Pharmaceutical (Chengdu), recently received the FDA inspection report confirming the completion and passing of the on-site inspection.
/ 02 /
Capital Information
1) Eli Lilly's Actual Controller Proposes Implementation of Mid-Year Dividend for 2024
On July 17, Ailis announced that the actual controller proposed to implement the interim dividend for the 2024 fiscal year. It is recommended to distribute a cash dividend of 2.5 yuan (including tax) for every 10 shares based on the total share capital of 450 million shares. The company will not issue bonus shares or convert capital reserves into share capital.
2) Jet Bio is expected to report a 930% year-over-year increase in net profit for the first half of the year.
On July 17, Jet Bio announced that the estimated net profit for the first half of the year would be 30.5 million yuan, representing a year-on-year increase of 929.77%.
3) Medprin Biotech Expects a Year-on-Year Increase of 127.05%-177.51% in Net Profit for the First Half of the Year
On July 17, Medprin Medical announced that the estimated net profit for the first half of the year would be RMB 27 million–33 million, representing a year-on-year increase of 127.05% - 177.51%.
/ 03 /
Pharmaceutical News
1) Jemincare's Avatrombopag Maleate Tablets and Active Pharmaceutical Ingredients Approved for Marketing
On July 17, Jemincare announced the market launch of Avatrombopag Maleate Tablets (Specification: 20mg), applicable for adult patients with chronic liver disease-related thrombocytopenia (CLDT) undergoing elective diagnostic procedures or surgery.
2) Junshi Biosciences' Toripalimab New Indication Application for First-Line Treatment of Advanced Hepatocellular Carcinoma Accepted
On July 17, Junshi Biosciences announced that the NMPA has accepted the company's new indication marketing application for toripalimab, an anti-PD-1 antibody, in combination with bevacizumab, for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).
/ 04 /
Instrument Tracking
1) CrownBio Medical Intracranial Pressure Monitor Registration Terminated
On July 17, according to the NMPA website, the registration of Crown Bioscience's intracranial pressure monitor was terminated.
2) Dimak Pharmaceuticals' Non-Compliant PTCA Balloon Dilation Catheter Approved for Marketing
On July 17, according to the NMPA website, Dima Medical's non-compliant PTCA balloon dilation catheter was approved for marketing.
3) Multiple products, including the Stryker stent system, have been approved for marketing.
On July 17, according to the NMPA website, multiple products from Stryker, including stent systems and balloon guiding catheters, were approved for marketing.
4) Edwards Annuloplasty Ring Approved for Marketing
On July 17, according to the NMPA website, Edwards annuloplasty ring was approved for marketing.
5) Boston Scientific Biliary Stent Approved for Marketing
On July 17, according to the NMPA website, Boston Scientific's biliary stent (equipped with the NaviFlexRX delivery system) was approved for marketing.
/ 05 /
Overseas Pharmaceutical News
1) Philips recalls multiple ventilator models in the U.S. at the highest level, two of which are sold in China
Recently, the FDA announced the highest-level recall of several respiratory machine products under Philips. The recalled products are mainly used to treat obstructive sleep apnea syndrome. Due to the failure of the ventilator's malfunction alarm device, it may lead to treatment interruption or failure, and could also cause insufficient ventilation, hypoxemia, hypercapnia, respiratory failure, or even death in vulnerable patients. Currently, two of the recalled products have entered the Chinese market.
2) Johnson & Johnson's Q2 Sales Reach $22.447 Billion, Up 4.3% Year-over-Year
On July 17, Johnson & Johnson released its financial report, showing Q2 sales of $22.447 billion, a year-on-year increase of 4.3%; adjusted net profit was $6.840 billion, up 1.6% year-on-year. Johnson & Johnson forecasts 2024 sales to be between $88 billion and $88.4 billion.
3) New hair growth device FoLix receives FDA approval for market launch
On July 17, FoLix, the world's first fractional laser hair growth device, was approved by the FDA for marketing. FoLix can be personalized based on the treatment area type and patient tolerance, utilizing precise laser pulse microbeams to uniformly irradiate tissue, stimulating hair follicles through the body’s natural healing process, increasing both hair count and follicular units. Results can be achieved within a 4-6 month treatment course without chemicals, needles, anesthesia, or surgery.
4) Positive Phase I Results for Roche's Oral GLP-1
On July 17, Roche announced positive results from two treatment groups in the Phase I clinical trial of oral GLP-1 CT-996. The data showed that obese subjects without type 2 diabetes who received CT-996 treatment experienced an average placebo-adjusted weight loss of -6.1% (p <0.001) after 4 weeks.
Text by Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
